WO2005032483A3 - Polysaccharides for pulmonary delivery of active agents - Google Patents

Polysaccharides for pulmonary delivery of active agents Download PDF

Info

Publication number
WO2005032483A3
WO2005032483A3 PCT/US2004/032613 US2004032613W WO2005032483A3 WO 2005032483 A3 WO2005032483 A3 WO 2005032483A3 US 2004032613 W US2004032613 W US 2004032613W WO 2005032483 A3 WO2005032483 A3 WO 2005032483A3
Authority
WO
WIPO (PCT)
Prior art keywords
pulmonary delivery
polysaccharides
active agents
prophylactic
therapeutic
Prior art date
Application number
PCT/US2004/032613
Other languages
French (fr)
Other versions
WO2005032483A2 (en
Inventor
Thomas Richardson
Ganesh Venkataraman
Yi Wei Qi
Michele Picard
Original Assignee
Momenta Pharmaceuticals Inc
Thomas Richardson
Ganesh Venkataraman
Yi Wei Qi
Michele Picard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc, Thomas Richardson, Ganesh Venkataraman, Yi Wei Qi, Michele Picard filed Critical Momenta Pharmaceuticals Inc
Priority to CA002540699A priority Critical patent/CA2540699A1/en
Priority to JP2006534220A priority patent/JP2007517771A/en
Priority to EP04809856A priority patent/EP1667633A4/en
Priority to AU2004278013A priority patent/AU2004278013B2/en
Publication of WO2005032483A2 publication Critical patent/WO2005032483A2/en
Publication of WO2005032483A3 publication Critical patent/WO2005032483A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Formulation for pulmonary delivery of a therapeutic, prophylactic, or diagnostic agent including a low molecular weight heparin and a therapeutic, prophylactic, or diagnostic agent.
PCT/US2004/032613 2003-10-01 2004-10-01 Polysaccharides for pulmonary delivery of active agents WO2005032483A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002540699A CA2540699A1 (en) 2003-10-01 2004-10-01 Polysaccharides for pulmonary delivery of active agents
JP2006534220A JP2007517771A (en) 2003-10-01 2004-10-01 Polysaccharides for pulmonary delivery of active substances
EP04809856A EP1667633A4 (en) 2003-10-01 2004-10-01 Polysaccharides for pulmonary delivery of active agents
AU2004278013A AU2004278013B2 (en) 2003-10-01 2004-10-01 Polysaccharides for pulmonary delivery of active agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50806203P 2003-10-01 2003-10-01
US60/508,062 2003-10-01
US58086904P 2004-06-18 2004-06-18
US60/580,869 2004-06-18

Publications (2)

Publication Number Publication Date
WO2005032483A2 WO2005032483A2 (en) 2005-04-14
WO2005032483A3 true WO2005032483A3 (en) 2007-05-31

Family

ID=34426034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/032613 WO2005032483A2 (en) 2003-10-01 2004-10-01 Polysaccharides for pulmonary delivery of active agents

Country Status (6)

Country Link
US (1) US7560444B2 (en)
EP (1) EP1667633A4 (en)
JP (1) JP2007517771A (en)
AU (1) AU2004278013B2 (en)
CA (1) CA2540699A1 (en)
WO (1) WO2005032483A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003273328A1 (en) * 2002-09-18 2004-04-08 Infineon Technologies Ag Nitride and polysilicon interface with titanium layer
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
CA2614068A1 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
AU2005287397A1 (en) * 2004-06-30 2006-03-30 Paul L. Deangelis Methods of selectively treating diseases with specific glycosaminoglycan polymers
CA2652797A1 (en) * 2006-05-18 2007-11-29 Tika Laekemedel Ab Methods for the delivery of a .beta.2 agonist to induce bronchodilation and formulations for use in the same
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
CA2795360A1 (en) 2010-04-16 2011-10-20 Momenta Pharmaceuticals, Inc. Tissue targeting
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
CA2910837A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
EP3344064A4 (en) * 2015-03-24 2019-08-07 Advanced Aesthetic Technologies, Inc. Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems
JP6879216B2 (en) * 2015-12-28 2021-06-02 味の素株式会社 Method for producing heparan sulfate having anticoagulant activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
WO2003068188A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Combination therapy for respiratory disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
CZ232593A3 (en) * 1991-05-02 1994-07-13 Yeda Res & Dev Pharmaceutical preparation for preventing and/or therapy of pathological states
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ATE299892T1 (en) * 1994-05-18 2005-08-15 Nektar Therapeutics METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
AU2440802A (en) * 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
WO2003068187A1 (en) 2002-02-18 2003-08-21 University Of Southampton Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
JP2005521695A (en) * 2002-03-20 2005-07-21 アドバンスト インハレーション リサーチ，インコーポレイテッド Method of administering growth hormone by pulmonary delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
WO2003068188A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Combination therapy for respiratory disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATH P.M. ET AL.: "Low Molecular Weight Heparin in Acute Stroke", EXP. OPIN. ON INVEST. DRUGS, vol. 7, no. 8, 1998, pages 1323 - 1330, XP000965050 *
HUHLE G. ET AL.: "Comparison of Three Heparin Bovine Serum Albumin Binding Methods for Production of Antiheparin Antibodies", SEMINARS IN THROMBOSIS AND HEMOSTASIS, vol. 20, no. 2, 1994, pages 193 - 204, XP008058534 *
THORPE P.E. ET AL.: "Heparin-Steroid Conjugates: New Angiogenesis Inhibitors with Antitumor Activity in Mice", CANCER RESEARCH, vol. 53, July 1993 (1993-07-01), pages 3000 - 3007, XP003011137 *

Also Published As

Publication number Publication date
US20050207988A1 (en) 2005-09-22
EP1667633A2 (en) 2006-06-14
AU2004278013A1 (en) 2005-04-14
CA2540699A1 (en) 2005-04-14
WO2005032483A2 (en) 2005-04-14
EP1667633A4 (en) 2008-10-08
JP2007517771A (en) 2007-07-05
US7560444B2 (en) 2009-07-14
AU2004278013B2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2005032483A3 (en) Polysaccharides for pulmonary delivery of active agents
AU2003258209A1 (en) Active agent delivery systems, medical devices, and methods
WO2004064769A3 (en) Methods for making and using topical delivery agents
WO2001049258A3 (en) Methods and compositions for improved delivery devices
HRP20060240T3 (en) Intranasal formulation of rotigotine
WO2005044224A3 (en) Drug delivery system based on polymer nanoshells
WO2005058366A3 (en) Compositions comprising two different populations of polymer-active agent conjugates
WO2006121963A3 (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
WO2006116718A3 (en) Pharma-informatics system
WO2005051292A3 (en) Devices systems, and methods to fixate tissue within the regions of the body, such as the pharyngeal conduit
WO2006044421A3 (en) Cardiac safe, rapid medication delivery
WO2007019554A3 (en) Polysaccharides for delivery of active agents
WO2006121964A3 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
WO2006014348A3 (en) Spray composition having a deposition control agent
WO2004082634A3 (en) Facially amphiphilic polymers and oligomers and uses thereof
SE0101932D0 (en) Pharmaceutical combinations
HRP20050342B1 (en) Pharmaceutical formulation of olanzapine
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
AU2002357972A1 (en) Heparin-containing ophthalmic agent
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2003018059A3 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
EP1719515A3 (en) Glycyrrhizin or derivatives thereof for treating or preventing togavirus infections
WO2004089964A8 (en) Lipid-regulating agent and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004278013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004809856

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2540699

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006534220

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004278013

Country of ref document: AU

Date of ref document: 20041001

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004278013

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004809856

Country of ref document: EP